|
|
Article: Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc.
- Article from:
- Blood Weekly
- Article date:
- November 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Shenzhen Beike Biotechnology Co. Ltd. ( http://www.beikebiotech.com/ ), China's leading stem cell research and regenerative medicine company, announced that it has entered into an agreement with Yokohama-based Biomaster Inc. ( http://www.biomaster.jp/ ) for investment in its advanced technologies. Biomaster specializes in research and commercialization of adipose-based stem cell therapies. Beike, along with two investment companies, has taken a significant share in Biomaster, secured a seat on the board, and is involved in the company's strategic positioning in preparation for an eventual IPO (see also Regenerative Medicine).
Since its inception in 2002, ...